Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic

  • Heron Therapeutics (NASDAQ:HRTX) on Tuesday said that the U.S. Food and Drug Administration (FDA) had acknowledged the receipt of the company’s prior approval supplement application for Zynrelef extended-release solution VAN.
  • The company added that the FDA has assigned a PDUFA date of September 23, 2024.
  • Press release.